[go: up one dir, main page]

MX2014001190A - Solucion inyectable de al menos insulina basal. - Google Patents

Solucion inyectable de al menos insulina basal.

Info

Publication number
MX2014001190A
MX2014001190A MX2014001190A MX2014001190A MX2014001190A MX 2014001190 A MX2014001190 A MX 2014001190A MX 2014001190 A MX2014001190 A MX 2014001190A MX 2014001190 A MX2014001190 A MX 2014001190A MX 2014001190 A MX2014001190 A MX 2014001190A
Authority
MX
Mexico
Prior art keywords
type
basal insulin
radicals
injectable solution
cooh
Prior art date
Application number
MX2014001190A
Other languages
English (en)
Inventor
Olivier Soula
GéRARD SOULA
Jeff Tonnar
Alexandre Geissler
Original Assignee
Adocia
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FR1157291A external-priority patent/FR2978918B1/fr
Priority claimed from FR1162445A external-priority patent/FR2984749A1/fr
Application filed by Adocia filed Critical Adocia
Publication of MX2014001190A publication Critical patent/MX2014001190A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/721—Dextrans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La invención se refiere a una solución inyectable que tiene un pH de 7, y que incluye al menos un tipo de insulina basal, el pI de la cual está entre 5.8 y 8.5. La invención se refiere a una composición en la forma de una solución acuosa inyectable, el pH de la cual está entre 6.0 y 8.0, incluyendo al menos: a) un tipo de insulina basal, el punto isoeléctrico (pI) de la cual está entre 5.8 y 8.5; y b) un dextrano substituido con radicales que tienen portadores de carboxilato y radicales hidrofóbicos de las fórmulas I o II, en donde R es -OH o es seleccionado del grupo que consiste de los radicales o-(f-[A]-COOH), o-(g-[B]-k-[D])m, D que comprende al menos una cadena de alquilo que comprende al menos 8 átomos de carbono, en donde R es -OH o un radical -(f-[A]-COOH)n, y R' se selecciona del grupo que consiste de los radicales o-CH2NH- [E] (-o- [F] )t y o-C(O)NH- [E] - (o- [F])t.
MX2014001190A 2011-08-10 2012-08-09 Solucion inyectable de al menos insulina basal. MX2014001190A (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201161522031P 2011-08-10 2011-08-10
FR1157291A FR2978918B1 (fr) 2011-08-10 2011-08-10 Solution injectable a ph7 comprenant au moins une insuline basale dont le pi est compris entre 5,8 et 8,5
US201161579966P 2011-12-23 2011-12-23
FR1162445A FR2984749A1 (fr) 2011-12-23 2011-12-23 Solution injectable a ph 7 comprenant au moins une insuline basale dont le pi est compris entre 5,8 et 8,5 en combinaison avec une hormone gastro-intestinale a visee therapeutique
PCT/FR2012/051880 WO2013021143A1 (fr) 2011-08-10 2012-08-09 Solution injectable d'au moins une insuline basale

Publications (1)

Publication Number Publication Date
MX2014001190A true MX2014001190A (es) 2014-05-12

Family

ID=47667929

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014001190A MX2014001190A (es) 2011-08-10 2012-08-09 Solucion inyectable de al menos insulina basal.

Country Status (14)

Country Link
US (3) US9089476B2 (es)
EP (2) EP3053590A1 (es)
JP (1) JP5950477B2 (es)
KR (1) KR101810055B1 (es)
CN (1) CN103889442B (es)
AU (1) AU2012293463B2 (es)
BR (1) BR112014002986A2 (es)
CA (1) CA2843586A1 (es)
DK (1) DK2741765T3 (es)
IL (1) IL230611A (es)
MX (1) MX2014001190A (es)
RU (1) RU2578460C2 (es)
WO (1) WO2013021143A1 (es)
ZA (1) ZA201400773B (es)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2843586A1 (fr) 2011-08-10 2013-02-14 Adocia Solution injectable d'au moins une insuline basale
CN104114155B (zh) 2012-01-09 2019-02-15 阿道恰公司 Ph为7并且至少包含pi为5.8至8.5之基础胰岛素和经取代共聚(氨基酸)的可注射溶液
US20150314003A2 (en) 2012-08-09 2015-11-05 Adocia Injectable solution at ph 7 comprising at least one basal insulin the isoelectric point of which is between 5.8 and 8.5 and a hydrophobized anionic polymer
UA116217C2 (uk) 2012-10-09 2018-02-26 Санофі Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону
DK2919804T3 (en) 2012-11-13 2018-05-14 Adocia Rapidly acting insulin formulation comprising a substituted anionic compound
FR3001895B1 (fr) * 2013-02-12 2015-07-03 Adocia Solution injectable a ph7 comprenant au moins une insuline basale dont le point isoelectrique est compris en 5,8 et 8,5 et un compose anionique porteur de charges carboxylates et de radicaux hydrophobes
SI2934568T1 (en) 2012-12-21 2018-03-30 Sanofi Dual GLP1 / GIP or trigonal agonists GLP1 / GIP / glucagon
WO2015044922A1 (en) 2013-09-30 2015-04-02 Wockhardt Limited Pharmaceutical composition
WO2015086729A1 (en) 2013-12-13 2015-06-18 Sanofi Dual glp-1/gip receptor agonists
TW201609795A (zh) 2013-12-13 2016-03-16 賽諾菲公司 作為雙重ｇｌｐ－１／ｇｉｐ受體促效劑的艾塞那肽－４（ｅｘｅｎｄｉｎ－４）胜肽類似物
TW201609796A (zh) 2013-12-13 2016-03-16 賽諾菲公司 非醯化之艾塞那肽－４（ｅｘｅｎｄｉｎ－４）胜肽類似物
TW201609797A (zh) 2013-12-13 2016-03-16 賽諾菲公司 雙重ｇｌｐ－１／升糖素受體促效劑
TW201625668A (zh) 2014-04-07 2016-07-16 賽諾菲公司 作為胜肽性雙重ｇｌｐ－１／昇糖素受體激動劑之艾塞那肽－４衍生物
TW201625670A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自ｅｘｅｎｄｉｎ－４之雙重ｇｌｐ－１／升糖素受體促效劑
TW201625669A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自艾塞那肽－４（Ｅｘｅｎｄｉｎ－４）之肽類雙重ＧＬＰ－１／升糖素受體促效劑
FR3020952B1 (fr) * 2014-05-14 2017-09-08 Adocia Formulation a action rapide d'insuline comprenant un compose anionique substitue et un compose polyanionique
FR3020947B1 (fr) 2014-05-14 2018-08-31 Adocia Composition aqueuse comprenant au moins une proteine et un agent solubilisant, sa preparation et ses utilisations
US9795678B2 (en) 2014-05-14 2017-10-24 Adocia Fast-acting insulin composition comprising a substituted anionic compound and a polyanionic compound
US9932381B2 (en) 2014-06-18 2018-04-03 Sanofi Exendin-4 derivatives as selective glucagon receptor agonists
AR105319A1 (es) 2015-06-05 2017-09-27 Sanofi Sa Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico
TW201706291A (zh) 2015-07-10 2017-02-16 賽諾菲公司 作為選擇性肽雙重ｇｌｐ－１／升糖素受體促效劑之新毒蜥外泌肽（ｅｘｅｎｄｉｎ－４）衍生物
EP3344231B1 (en) * 2015-09-04 2022-04-13 Latitude Pharmaceuticals, Inc. Stabilized glucagon solutions
FR3043557B1 (fr) 2015-11-16 2019-05-31 Adocia Composition a action rapide d'insuline comprenant un citrate substitue
EP3377038A1 (fr) * 2015-11-16 2018-09-26 Adocia Composition a action rapide d'insuline comprenant un compose anionique substitue et un compose polyanionique
AU2017223274B2 (en) * 2016-02-25 2024-08-15 Wockhardt Limited Pharmaceutical composition of insulin glargine and amino acids
GB201607918D0 (en) 2016-05-06 2016-06-22 Arecor Ltd Novel formulations
FR3052072A1 (fr) 2016-06-07 2017-12-08 Adocia Solution injectable a ph 7 comprenant au moins une insuline basale dont le pi est compris entre 5,8 et 8,5 et un co-polyaminoacide porteur de charges carboxylates et de radicaux hydrophobes
JP7145849B2 (ja) 2016-09-29 2022-10-03 アレコル リミテッド 新規の製剤
US10463717B2 (en) * 2016-12-27 2019-11-05 Adocia Compositions in the form of an injectable aqueous solution comprising amylin, an amylin receptor agonist or an amylin analog, and a co-polyamino acid
FR3070264A1 (fr) 2017-08-24 2019-03-01 Adocia Solution injectable a ph 7 comprenant au moins une insuline basale dont le pi est compris de 5,8 a 8,5 et un co-polyaminoacide porteur de charges carboxylates et de radicaux hydrophobes
FR3083088B1 (fr) 2018-06-29 2020-10-02 Adocia Solution injectable a ph 7 comprenant au moins une insuline basale dont le pi est compris entre 5,8 et 8,5 et un co-polyaminoacide porteur de charges carboxylates et de radicaux hydrophobes
WO2019110625A1 (fr) 2017-12-06 2019-06-13 Adocia Solution injectable a ph 7 comprenant au moins une insuline basale dont le pi est compris entre 5,8 et 8,5 et un co-polyaminoacide porteur de charges carboxylates et de radicaux hydrophobes
FR3083089A1 (fr) 2018-06-29 2020-01-03 Adocia Solution injectable a ph 7 comprenant au moins une insuline basale dont le pi est compris entre 5,8 et 8,5 et un co-polyaminoacide porteur de charges carboxylates et de radicaux hydrophobes
BR112020011570A2 (pt) 2017-12-07 2020-12-08 Adocia Solução injetável a um ph 7 compreendendo pelo menos uma insulina basal apresentando um pi entre 5,8 e 8,5 e um co-poliaminoácido contendo cargas de carboxilato e radicais hidrofóbicos
KR20240171197A (ko) 2017-12-07 2024-12-06 아도시아 pI가 5.8 내지 8.5인 적어도 1종의 기저 인슐린, 및 카복실산염 전하 및 소수성 라디칼을 보유하는 코-폴리아미노산을 포함하는 pH 7의 주사용 용액
EP4671300A2 (fr) 2017-12-07 2025-12-31 Adocia Solution injectable a ph 7 comprenant au moins une insuline basale dont le pi est compris entre 5,8 et 8,5 et un co-polyaminoacide porteur de charges carboxylates et de radicaux hydrophobes
CN112040928A (zh) * 2018-04-04 2020-12-04 艾瑞克有限公司 用于递送胰岛素化合物的医用输注泵系统
IL277731B2 (en) * 2018-04-04 2024-03-01 Arecor Ltd Medical infusion pump system for the delivery of an insulin compound
IL277721B2 (en) * 2018-04-04 2024-03-01 Arecor Ltd Medical infusion pump system for the delivery of an insulin compound
JP2021528474A (ja) * 2018-06-29 2021-10-21 ビーエイエスエフ・ソシエタス・エウロパエアＢａｓｆ Ｓｅ エステルアミン塩
FR3083700B1 (fr) * 2018-07-13 2021-03-12 Adocia Formulation thermostable d'insuline humaine a21g
US20200179489A1 (en) 2018-12-07 2020-06-11 Adocia Injectable solution at ph 7 comprising at least one basal insulin which pi is from 5.8 to 8.5 and a co-polyamino-acid bearing carboxylate charges and hydrophobic radicals and a limited amount of m-cresol

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2387201A (en) 1942-01-12 1945-10-16 Bonneville Ltd Mono-acyl ethylene diamines
WO1985001890A1 (fr) 1983-10-26 1985-05-09 Kanebo, Ltd. Agent emulsifiant proteique, son procede de preparation et preparation cosmetique emulsifiee le contenant
DE3837825A1 (de) 1988-11-08 1990-05-10 Hoechst Ag Neue insulinderivate, ihre verwendung und eine sie enthaltende pharmazeutische zubereitung
ES2334555T3 (es) 1999-04-09 2010-03-12 Amag Pharmaceuticals, Inc. Oxidos de hierro coloidal recubiertos estables frente al calor.
FR2801226B1 (fr) 1999-11-23 2002-01-25 Flamel Tech Sa Suspension colloidale de particules submicroniques de vectorisation de principes actifs et son mode de preparation
IL140844A0 (en) 2001-01-10 2002-02-10 Polygene Ltd Cationic polysaccharide compositions
HUP0700126A2 (en) 2001-12-20 2007-06-28 Lilly Co Eli Insulin molecule having protracted time action
FR2840614B1 (fr) 2002-06-07 2004-08-27 Flamel Tech Sa Polyaminoacides fonctionnalises par de l'alpha-tocopherol et leurs applications notamment therapeutiques
DE10227232A1 (de) * 2002-06-18 2004-01-15 Aventis Pharma Deutschland Gmbh Saure Insulinzubereitungen mit verbesserter Stabilität
AU2003294056A1 (en) 2002-12-04 2004-07-29 Flamel Technologies Polyamino acids functionalized by at least one (oligo)amino acid group and therapeutic uses
WO2004096854A2 (en) 2003-04-29 2004-11-11 Eli Lilly And Company Insulin analogs having protracted time action
CN113304250A (zh) * 2003-11-20 2021-08-27 诺和诺德股份有限公司 对于生产和用于注射装置中是最佳的含有丙二醇的肽制剂
FR2862536B1 (fr) 2003-11-21 2007-11-23 Flamel Tech Sa Formulations pharmaceutiques pour la liberation prolongee de principe(s) actif(s), ainsi que leurs applications notamment therapeutiques
FR2873040B1 (fr) 2004-07-19 2007-11-30 Flamel Technologies Sa Formulation colloidale d'insuline longue action et sa preparation
WO2006051103A2 (en) 2004-11-12 2006-05-18 Novo Nordisk A/S Stable formulations of peptides
WO2006079019A2 (en) 2005-01-21 2006-07-27 Alza Corporation Therapeutic peptide formulations for coating microneedles with improved stabitity containing at least one counterion
BRPI0710315A2 (pt) 2006-04-07 2011-08-09 Adocia dextrano e/ou derivado de dextrano, composição farmacêutica, métodos de tratamento ou formulação de medicamentos, e, utilização de destranos e/ou derivados de dextranos e/ou de composições
MX2008013165A (es) 2006-04-12 2009-01-29 Biodel Inc Formulaciones de combinacion de insulina de accion rapida y accion larga.
US8679540B2 (en) 2006-06-09 2014-03-25 Flamel Technologies Pharmaceutical formulations for the prolonged release of active principle(s), and their applications, especially therapeutic applications
FR2902007B1 (fr) 2006-06-09 2012-01-13 Flamel Tech Sa Formulations pharmaceutiques pour la liberation prolongee de principe(s) actif(s) ainsi que leurs applications notamment therapeutiques
CA2662628C (en) 2006-09-07 2016-02-09 Industrial Research Limited Acyclic amine inhibitors of nucleoside phosphorylases and hydrolases
FR2915683B1 (fr) 2007-05-03 2009-08-07 Flamel Technologies Sa Formulations pharmaceutiques auto-precipitantes pour la liberation modifiee de principe actif
FR2919188B1 (fr) * 2007-07-27 2010-02-26 Proteins & Peptides Man Complexes entre un polymere amphiphile et une proteine osteogenique appartenant a la famille des bmps
EP2178909B1 (en) 2007-08-13 2015-10-21 Novo Nordisk A/S Rapid acting insulin analogues
PT2597103T (pt) * 2007-11-16 2017-02-08 Novo Nordisk As Composições farmacêuticas contendo insulina e um péptido insulinotrófico
TWI394580B (zh) * 2008-04-28 2013-05-01 Halozyme Inc 超快起作用胰島素組成物
TWI451876B (zh) * 2008-06-13 2014-09-11 Lilly Co Eli 聚乙二醇化之離脯胰島素化合物
US20100069292A1 (en) * 2008-09-02 2010-03-18 Biodel, Inc. Insulin with a basal release profile
US20100167984A1 (en) 2008-09-26 2010-07-01 Adocia Complex between human insulin and an amphiphilic polymer and use of this complex in the preparation of a fast-acting human insulin formulation
FR2940802A1 (fr) * 2008-10-10 2010-07-09 Adocia Complexe entre l'insuline humaine et un polymere amphiphile et utilisation de ce complexe pour la preparation d'une formulation d'insuline humaine rapide.
US8426382B2 (en) * 2008-10-06 2013-04-23 Adocia Polysaccharides comprising carboxyl functional groups substituted by a hydrophobic alcohol derivative
FR2936800B1 (fr) * 2008-10-06 2010-12-31 Adocia Polysaccharide comportant des groupes fonctionnels carboxyles substitues par un derive d'alcool hydrophobe
WO2010053140A1 (ja) 2008-11-05 2010-05-14 国立大学法人 東京医科歯科大学 ヒアルロン酸誘導体、およびその医薬組成物
CN102216462A (zh) 2008-11-17 2011-10-12 安龙制药公司 用于核酸递送系统的支化阳离子脂质
FR2948573B1 (fr) * 2009-07-31 2011-11-18 Adocia Nouvelle forme d'administration de complexes de proteines osteogeniques
FR2944448B1 (fr) * 2008-12-23 2012-01-13 Adocia Composition pharmaceutique stable comprenant au moins un anticorps monodonal et au moins un polysacharide amphiphile comprenant des substituants derives d'alcools hydrofobes ou d'amines hydrophobes.
EP2376523A4 (en) * 2009-01-13 2012-11-28 Ge Healthcare Bio Sciences Ab PRECIPITATION OF BIOMOLECULES USING NEGATIVELY LOADED POLYMERS
US9060927B2 (en) * 2009-03-03 2015-06-23 Biodel Inc. Insulin formulations for rapid uptake
US9018190B2 (en) 2009-03-27 2015-04-28 Adocia Functionalized oligosaccharides
FR2943538B1 (fr) * 2009-03-27 2011-05-20 Adocia Formulation a action rapide d'insuline recombinante humaine
FR2956116A1 (fr) * 2010-02-09 2011-08-12 Adocia Complexes polysaccharide/bmp-7 solubles a ph physiologique
FR2958646B1 (fr) * 2010-04-07 2012-05-18 Adocia Polysaccharides comportant des groupes fonctionnels carboxyles substitues par un derive d'acide hydrophobe.
CN102834117B (zh) 2010-02-09 2015-11-25 阿道恰公司 通过至少两个由至少三价的间隔物所携带的疏水基团进行官能化的阴离子多糖
FR2958647B1 (fr) 2010-04-08 2013-08-23 Adocia Polysaccharides comportant des groupes fonctionnels carboxyles substitues par un derive hydrophobe porte par un spacer au moins trivalent.
EP2388723A1 (en) 2010-05-18 2011-11-23 University College Cork-National University of Ireland, Cork Method of assessing allergic status in a subject
AU2011202239C1 (en) 2010-05-19 2017-03-16 Sanofi Long-acting formulations of insulins
EP2389945A1 (en) 2010-05-28 2011-11-30 Sanofi-Aventis Deutschland GmbH Pharmaceutical composition comprising AVE0010 and insulin glargine
WO2012153071A2 (fr) 2011-05-10 2012-11-15 Adocia Polysaccharides à degré de fonctionnalisation modulable
EP2828297A1 (fr) 2011-05-10 2015-01-28 Adocia Oligosaccharides fonctionnalisés
CA2843586A1 (fr) 2011-08-10 2013-02-14 Adocia Solution injectable d'au moins une insuline basale
FR2985429B1 (fr) 2012-01-09 2016-07-29 Adocia Solution injectable a ph 7 comprenant au moins une insuline basale dont le pi est compris entre 5,8 et 8,5 et un polyaminoacide substitue obtenu par un procede de polymerisation controle
FR2985428B1 (fr) 2012-01-09 2016-05-27 Adocia Solution injectable a ph 7 comprenant au moins une insuline basale dont le pi est compris entre 5,8 et 8,5 et un polyaminoacide substitue
CN104114155B (zh) 2012-01-09 2019-02-15 阿道恰公司 Ph为7并且至少包含pi为5.8至8.5之基础胰岛素和经取代共聚(氨基酸)的可注射溶液
EP2814459A1 (en) 2012-02-17 2014-12-24 Massachusetts Institute Of Technology Self-regulated peptide hydrogel for insulin delivery
JP2016505523A (ja) 2012-11-13 2016-02-25 アドシア 離散数の糖単位から構成される主骨格から成る置換されたアニオン性化合物
DK2919804T3 (en) 2012-11-13 2018-05-14 Adocia Rapidly acting insulin formulation comprising a substituted anionic compound

Also Published As

Publication number Publication date
DK2741765T3 (en) 2016-06-13
EP3053590A1 (fr) 2016-08-10
KR20140051384A (ko) 2014-04-30
IL230611A0 (en) 2014-03-31
JP5950477B2 (ja) 2016-07-13
US20180311316A1 (en) 2018-11-01
RU2014108829A (ru) 2015-09-20
CA2843586A1 (fr) 2013-02-14
ZA201400773B (en) 2016-11-30
US9089476B2 (en) 2015-07-28
AU2012293463A1 (en) 2014-03-06
US20170182131A9 (en) 2017-06-29
CN103889442B (zh) 2016-12-28
RU2578460C2 (ru) 2016-03-27
IL230611A (en) 2016-10-31
KR101810055B1 (ko) 2017-12-18
US20130065826A1 (en) 2013-03-14
AU2012293463B2 (en) 2016-08-04
WO2013021143A1 (fr) 2013-02-14
US20150250858A1 (en) 2015-09-10
CN103889442A (zh) 2014-06-25
EP2741765B1 (fr) 2016-03-30
JP2014521716A (ja) 2014-08-28
EP2741765B9 (fr) 2016-09-28
EP2741765A1 (fr) 2014-06-18
BR112014002986A2 (pt) 2017-06-13

Similar Documents

Publication Publication Date Title
MX2014001190A (es) Solucion inyectable de al menos insulina basal.
SA518400588B1 (ar) محلول قابل للحقن عند الرقم الهيدروجيني 7يشتمل على أنسولين قاعدي واحد على (pi)الأقل تتراوح نقطة التعادل الكهربائي الخاصة به من5.8إلى8.5وحمض بولي أميني مشترك يحمل شحنات كربوكسيلات وجذور كارهة للماء
MY192981A (en) Cyclosporine analogue molecules modified at amino acid 1 and 3
EA202090053A2 (ru) Способы и композиции для лечения неэффективного эритропоэза
MX2025009746A (es) Solucion inyectable a ph 7 que comprende al menos una insulina basal que tiene un pi de entre 5.8 y 8.5 y un copoliaminoacido con cargas de carboxilato y radicales hidrofobicos
MX2019004378A (es) Edulcorante de estevia altamente soluble.
AU2012282543A8 (en) Hydrophobised calcium carbonate particles
BR112014013780A8 (pt) transportador de seringa
UA105229C2 (uk) Фармацевтичний склад
MX2015013806A (es) Polieteraminas a base de 1,3-dialcoholes.
BR112012018674A8 (pt) Usos de pelo menos uma polietilenimina, e de uma suspensão, e, método para aumentar o ph de uma suspensão aquosa
BR112013005398A2 (pt) "método para aumentar a estabilidade de um licor do processo bayer"
MX2015008369A (es) Composiciones de diclofenaco.
PH12015500863A1 (en) Handleable calco-magnesian suspension
BR112014010374A2 (pt) alimento para animais, uso de uma xilanase hiper-termofílica e hiper-termoestável, uso do alimento para animais e processo para produzir alimento para animais
NZ716341A (en) Glyceride composition
MX347919B (es) Composiciones de tetraciclina.
BR112014012688A8 (pt) elemento e método de compensação de flutuação
BR112013002230A2 (pt) marcadores de peso molecular de acetato de glatiramer
BR112012027550A2 (pt) uso de uma composição
MX2013008699A (es) Compuestos para reducir la produccion de beta-amiloide.
BR112012019920A2 (pt) derivados de piridazina úteis como agonístas de canabinoide-2.
BR112014010053A2 (pt) variantes de isopreno sintase com solubilidade aprimorada para produção de isopreno
BR112012002453A2 (pt) uso de 2-amino-2-metil-1-propanol(amp),e, método para aumentar o ph de uma suspensão aquosa.
BR112012031053A2 (pt) uso de 2-aminoetanol, e, método para aumentar o ph de uma suspensão aquosa.

Legal Events

Date Code Title Description
FG Grant or registration